Lanreotide extended-release aqueous-gel formulation, injected by patient, partner or healthcare provider in patients with acromegaly in the United States: 1-year data from the SODA registry.
about
Lanreotide Autogel 120 mg at extended dosing intervals in patients with acromegaly biochemically controlled with octreotide LAR: the LEAD study.Patient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly.Patient-focussed outcomes in acromegaly.Attitudes and preferences in patients with acromegaly on long-term treatment with somatostatin analogues.Lanreotide autogel(®): a review of its use in the treatment of patients with acromegaly.Lanreotide autogel in acromegaly - a decade on.A multicenter, observational study of lanreotide depot/autogel (LAN) in patients with acromegaly in the United States: 2-year experience from the SODA registry.New therapeutic agents for acromegaly.Prolonged preoperative treatment of acromegaly with Somatostatin analogs may improve surgical outcome in patients with invasive pituitary macroadenoma (Knosp grades 1-3): a retrospective cohort study conducted at a single center.The care continuum in acromegaly: how patients, nurses, and physicians can collaborate for successful treatment experiences.How are growth hormone and insulin-like growth factor-1 reported as markers for drug effectiveness in clinical acromegaly research? A comprehensive methodologic review.Screening for comorbid conditions in patients enrolled in the SODA registry: a 2-year observational analysis.
P2860
Q35981653-D781EE54-3BA9-4571-995B-726C1E80F48FQ36489627-E5F4F437-B880-4D80-9FA7-508269573A55Q37530996-03ECFFEC-44C2-4722-8142-F36B1E876E1EQ37641076-74D9824F-0F97-4D81-A403-E6173889FBE3Q38246440-2EDC37B0-1230-4A87-A1B7-9C9115D68328Q38259409-F7875683-9975-4E96-B8B9-080963A1AC29Q38373377-6F34423E-7E64-4607-AF53-AEAB0F852B23Q38648739-32432972-DD27-4C91-ADF4-B6E6C51F556FQ41624853-73FB1298-B351-48A8-B968-5B7D6A9B08D6Q42414991-5F29DECE-F0D4-40AD-9237-22B96A24919BQ54939988-0A7CB0E3-5B40-43BA-AEA9-A25A8A850CB9Q55293690-A5AB48EF-FB08-4D5E-A741-4557B495A36B
P2860
Lanreotide extended-release aqueous-gel formulation, injected by patient, partner or healthcare provider in patients with acromegaly in the United States: 1-year data from the SODA registry.
description
2014 nî lūn-bûn
@nan
2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Lanreotide extended-release aq ...... r data from the SODA registry.
@ast
Lanreotide extended-release aq ...... r data from the SODA registry.
@en
type
label
Lanreotide extended-release aq ...... r data from the SODA registry.
@ast
Lanreotide extended-release aq ...... r data from the SODA registry.
@en
prefLabel
Lanreotide extended-release aq ...... r data from the SODA registry.
@ast
Lanreotide extended-release aq ...... r data from the SODA registry.
@en
P2093
P2860
P1433
P1476
Lanreotide extended-release aq ...... r data from the SODA registry.
@en
P2093
Kathleen G Lomax
Mark Molitch
Murray B Gordon
Roberto Salvatori
Whitney W Woodmansee
P2860
P2888
P356
10.1007/S11102-012-0460-2
P577
2014-02-01T00:00:00Z